Emerging discoveries are reshaping the understanding of heart failure, highlighting the crucial role of gut microbiota in disease progression. The intricate relationship between gut health and cardiovascular function is becoming increasingly evident, revealing a bidirectional interaction known as the gut-heart axis. This dynamic connection suggests that imbalances in gut microbiota composition, known as gut dysbiosis, may contribute to cardiac dysfunction, inflammation, and metabolic disturbances that accelerate heart failure.

ADAMTS2, a member of the ADAMTS zinc metalloproteinase family, is widely recognized for its pivotal role as a procollagen I N-proteinase. This enzyme plays a crucial part in the maturation of fibrillar collagens, which are essential for maintaining the structural integrity of connective tissues. Beyond its traditional role, recent discoveries have revealed that ADAMTS2 is involved in a diverse range of biological processes that extend well beyond collagen maturation.

One of the biggest challenges in cancer treatment is that certain cancers reappear after chemotherapy—and an aggressive type of blood cancer called acute myeloid leukemia (AML) is notorious for this. Now, new research from The Jackson Laboratory (JAX) points to a previously unknown molecular mechanism behind that chemoresistance, and a way to potentially disarm it.

Abnormalities in tumor electrophysiology are key drivers of malignant tumor progression. This review systematically elaborates on its molecular mechanisms and clinical translation: Tumor cells regulate proliferation, maintenance of stemness, and metastasis through membrane potential depolarization and remodeling of specific "ion channel fingerprints". These electrophysiological characteristics interact with key signaling pathways to form a complex regulatory network (e.g., TRPV1 exhibits tissue-specific regulatory patterns in different tumors). Based on the above mechanisms, targeted ion channel modulators, therapeutic tumor electric fields, and nanodelivery platforms have shown significant efficacy in preclinical and clinical studies. Especially when combined with immunomodulatory strategies, they can reshape the tumor microenvironment and enhance anti-tumor immunity. Despite challenges such as treatment-related complications and the need to verify long-term efficacy, electrophysiology-targeted therapies still provide a highly promising new direction for precision oncology.

A research team led by Dr. Juyeon Jung at the Bio-Nano Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), has developed a nanobody-based technology that can precisely identify and attack only lung cancer cells, opening new possibilities for cancer therapy.

A new study has identified a set of plasma proteins that can predict whether patients with triple-negative breast cancer (TNBC) will respond to immunotherapy.